Table 1. Individual-Level Characteristics of the Study Cohort.
| Guideline from the American College of Obstetricians and Gynecologists on early pregnancy loss managementa | Total | ||||
|---|---|---|---|---|---|
| Before release (Jan 2016-Nov 2018) (n = 13 594) |
After release (Dec 2018-Dec 2020) (n = 8532) |
||||
| Mifepristone plus misoprostol |
Misoprostol alone | Mifepristone plus misoprostol |
Misoprostol alone | ||
| All states | |||||
| Total | 74 (0.54) | 13 520 (99.46) | 152 (1.78) | 8380 (98.22) | 22 126b |
| Patient age, median (IQR), y | 33.5 (30-39) | 33 (29-37) | 34 (32-37) | 33 (29-37) | 33 (29-37) |
| US region | |||||
| Midwest | 7 (0.2) | 2234 (61.3) | 8 (0.2) | 1397 (38.3) | 3646 |
| Northeast | 35 (1.1) | 1981 (60.9) | 61 (1.9) | 1176 (36.2) | 3253 |
| South | 6 (0.1) | 6617 (60.6) | 17 (0.2) | 4274 (39.2) | 10 914 |
| West | 26 (0.6) | 2681 (62.5) | 65 (1.5) | 1519 (35.4) | 4291 |
| Unknown | 0 | 7 (31.8) | 1 (4.5) | 14 (63.6) | 22 |
| Source of medications | |||||
| Prescription | 0 | 13 322 (61.7) | 1 (<1) | 8272 (38.3) | 21 595 |
| Clinic | 47 (11.5) | 198 (48.3) | 57 (13.9) | 108 (26.3) | 410 |
| Multiple sources | 27 (22.3) | 0 | 94 (77.7) | 0 | 121 |
| Unrestricted states c | |||||
| Before Nov 2018 (n = 18 828) | After Nov 2018 (n = 6697) | ||||
| Total | 73 (0.67) | 10 755 (99.33) | 148 (2.21) | 6549 (97.79) | 17 525d |
| Patient age, median (IQR), y | 34 (30-39) | 33 (29-37) | 34 (32-37) | 33 (29-37) | 33 (29-37) |
| US region | |||||
| Midwest | 7 (0.3) | 1359 (63.8) | 7 (0.3) | 758 (35.6) | 2131 |
| Northeast | 35 (1.1) | 1981 (60.9) | 61 (1.9) | 1176 (36.2) | 3253 |
| South | 5 (0.1) | 4925 (60.8) | 14 (0.2) | 3161 (39.0) | 8105 |
| West | 26 (0.6) | 2483 (61.9) | 65 (1.6) | 1440 (35.9) | 4014 |
| Unknown | 0 | 7 (31.8) | 1 (4.5) | 14 (63.6) | 22 |
| Source of medications | |||||
| Prescription | 0 | 10 592 (62.1) | 1 (<1) | 6461 (37.9) | 17 054 |
| Clinic | 47 (13.3) | 163 (46.0) | 56 (15.8) | 88 (24.9) | 354 |
| Multiple sources | 26 (22.2) | 0 | 91 (77.8) | 0 | 117 |
Data are expressed as No. (%) unless otherwise indicated.
Data represent 22 116 unique first-time patients receiving mifepristone plus misoprostol or misoprostol alone (22 116 had ≥1 miscarriage; 524 had ≥2 miscarriages [10 of whom received both treatments for different miscarriages, representing 22 126 patients receiving both treatments over time]; and 21 had 3 miscarriages) and 22 661 claims for mifepristone plus misoprostol and misoprostol alone. In 2016, 0.40% received mifepristone plus misoprostol and 99.60% received misoprostol alone; and in 2020, these percentages were 2.50% and 97.50%, respectively.
The 11 excluded states with restrictions on abortion care for fully insured private plans as of May 1, 2022, were Idaho, Indiana, Kansas, Kentucky, Michigan, Missouri, Nebraska, North Dakota, Oklahoma, Texas, and Utah.
Data represent 17 515 unique first-time patients receiving mifepristone plus misoprostol or misoprostol alone (17 515 had ≥1 miscarriage; 434 had ≥2 miscarriages [10 of whom received both treatments for different miscarriages, representing 17 525 patients receiving both treatments over time]; and 16 had 3 miscarriages) and 17 965 claims for mifepristone plus misoprostol and misoprostol alone. In 2016, 0.51% received mifepristone plus misoprostol and 99.49% received misoprostol alone; and in 2020, these percentages were 3.08% and 96.92%, respectively.